Login / Signup

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).

Ju Won KimKyungmin LeeJi Yoon LeeSook Ryun ParkYu Jung KimIn Gyu HwangWoo Kyun BaeJae Ho ByunJung Sun KimEun Joo KangJeeyun LeeSang Joon ShinWon Jin ChangEun-Ok KimJason K SaKyong-Hwa Park
Published in: Journal for immunotherapy of cancer (2024)
NCT04761744.
Keyphrases
  • phase ii study
  • dna damage
  • open label
  • locally advanced
  • squamous cell carcinoma
  • oxidative stress
  • small cell lung cancer
  • copy number
  • young adults
  • rectal cancer
  • placebo controlled